Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Ibrutinib + BR in Newly Diagnosed Mantle Cell Lymphoma
NCT01776840Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2013
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Janssen Pharmaceutical. Started May 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01776840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01776840.